Publication
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerChronic Lymphocytic Leukemia/Small Lymphocytic Lymphomacivic_curation1.00
- drugVenetoclaxcivic_curation1.00
- geneBCL2civic_curation1.00
- variantBCL2 G101Vcivic_curation1.00
Curated evidence
Evidence citing this paper (11)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32232486
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BTK C481R1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia | Predictive | C | Does Not Support Resistance | 2 | submitted | EID10374The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BTK C481Y1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia | Predictive | C | Supports Resistance | 2 | submitted | EID10373The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| PLCG2 D1140E1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia | Predictive | C | Supports Resistance | 2 | submitted | EID10372The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| PLCG2 N571S1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia | Predictive | C | Supports Resistance | 2 | submitted | EID10371The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 A113G1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 3 | submitted | EID8189Associated with venetoclax resistance in high-risk CLL post ibrutinib in "progressive CLL" PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 F104L1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 3 | submitted | EID8187Associated with venetoclax resistance in 2 high-risk CLL patients post ibrutinib in "progressive CLL" PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 F104S1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 3 | submitted | EID8186Associated with venetoclax resistance in high-risk CLL post ibrutinib in "progressive CLL" PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 G101A1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 4 | submitted | EID8184Associated with venetoclax resistance in high-risk CLL post ibrutinib in "progressive CLL" PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 G101V1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | C | Supports Resistance | 2 | accepted | EID8185The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC) PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 L119V1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 3 | submitted | EID8190Associated with venetoclax resistance in high-risk CLL post ibrutinib in "progressive CLL" PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |
| BCL2 R107_R110dup1 | ||||||||
| Venetoclax | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Predictive | B | Supports Resistance | 3 | submitted | EID8188Associated with venetoclax resistance in high-risk CLL patients post ibrutinib in 2 cases of "progressive CLL" and 1 case of Richter transformation PMID 32232486 · Lucas et al., 2020 · Open in CIViC | civic |